Characteristics of meningococcal meningitis in children in France;Caractéristiques des méningites à méningocoque de l'enfant en France

Archives de Pediatrie

Volumn 15, Issue SUPPL. 3, 2008, Pages

  Levy, C ^a,b   Taha, M K ^c   Weill Olivier, C ^a   Quinet, B ^a   Lecuyer A ^a,b   Alonso, J M ^c   Cohen, R ^a,b,d   Bingen, E ^a  

^a GPIP (Groupe de Pathologie Infectieuse Pediatrique) de la SFP (Societe Francaise de Pediatrie)   (France)

^b ACTIV Association Clinique et Therapeutique Infantile du Val de Marne   (France)

^c CENTRE NATIONAL DE RECHERCHES MÉTÉOROLOGIQUES   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CARBOHYDRATE; CEFOTAXIME; CEFTRIAXONE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD GROUP TYPING; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILD CARE; CLINICAL FEATURE; CONTROLLED STUDY; EPIDEMIC MENINGITIS; FRANCE; HEALTH SURVEY; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MORTALITY; NEISSERIA MENINGITIDIS; RISK FACTOR; SERODIAGNOSIS; SHOCK;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, BACTERIAL; MENINGITIS, MENINGOCOCCAL; RISK FACTORS; SEIZURES; SEROTYPING; SEX RATIO;

EID: 61349170731     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(08)75492-7     Document Type: Article

References (25)

1. Bingen E., Levy C., de la Rocque F., et al. Bacterial meningitis in children: a French prospective study. Clin Infect Dis 41 (2005) 1059-1063
2. Parent du Châtelet I, Taha MK, Lepoutre A, et al. Les infections invasives à méningocoque en France en 2007. Bull Epidemiol Hebdo 2008;sous presse.
3. Trotter C.L., and Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. Federation of European Microbiological Societies 31 (2007) 101-107
4. Segal S., and Pollard A.J. Vaccines against bacterial meningitis. Br Med Bull 72 (2004) 65-81
5. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 (2004) S274-S279
6. de Greeff S.C., de Melker H.E., Spanjaard L., et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25 (2006) 79-80
7. Gray S.J., Trotter C.L., Ramsay M.E., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 55 (2006) 887-896
8. Anonyme. Calendrier vaccinal. BEH 2008;16-17:131-8.
9. Taha M.K., and Alonso J.M. Meningococcal vaccines: to eradicate the disease, not the bacterium. Hum Vaccin 3 (2007) 149-152
10. Taha M.K., Zarantonelli M.L., Alonso J.M., et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 25 (2007) 2537-2538
11. Anonyme. http://afssaps.sante.fr/htm/5/rappe/data/rappe_enbvac.htm. 2007.
12. Parent du Châtelet I., Taha M.K., Lepoutre A., et al. Les infections invasives à méningocoque en France en 2006. Bull Epidemiol Hebd (2007) 51-52 437-41
13. Alonso J.M., and Taha M.K. Les infections à méningocoques en France : les données du Centre National de Référence. Médecine thérapeutique/Pédiatrie 5 (2002) 191-196
14. Levy C., Bingen E., Aujard Y., et al. Observatoires nationales des méningites bactériennes de l'enfant en France, résultats de 7 années d'étude. Arch Pediatr 15 Suppl 3 (2008) S99-S104
15. Rosenqvist E., Hoiby E.A., Wedege E., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63 (1995) 4642-4652
16. Parent du Châtelet I., and Taha M.K. Les infections invasives à méningocoque en France en 2005. Bull Epidemiol Hebd 49 (2006) 383-386
17. Taha M.K., Achtman M., Alonso J.M., et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 356 (2000) 2159
18. Traore Y., Njanpop-Lafourcade B.M., Adjogble K.L., et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 43 (2006) 817-822
19. Dragon-Durey M.A., and Fremeaux-Bacchi V. Déficits en protéins du complément en pathologie humaine. Presse Médicale 35 (2006) 861-870
20. Vazquez J.A., Arreaza L., Block C., et al. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 47 (2003) 3430-3434
21. Trotter C.L., Chandra M., Cano R., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31 (2007) 27-36
22. Zarantonelli M.L., Lancellotti M., Deghmane A.E., et al. Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 14 (2008) 467-472
23. Borrow R., and Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 5 (2006) 851-857
24. Kriz P., Giorgini D., Musilek M., et al. Microevolution through DNA exchange among strains of Neisseria meningitidis isolated during an outbreak in the Czech Republic. Res Microbiol 150 (1999) 273-280
25. Alonso JM, Taha MK, Vienne P, et al. Infections invasives à méningocoques 2001-2003 Données du Centre national de référence. http://www.invs.sante.fr/publications/2005/snmi/pdf/iim.pdf 2005.